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Bench to BedsideThe most prevalent form of cystic brosis arises from an 
amino acid deletion in the cystic brosis transmembrane 
conductance regulator, CFTR.  A recently approved 
treatment for individuals homozygous for this mutation 
combines a chemical corrector, which helps CFTR fold, 
and a potentiator that increases CFTR channel activity. 
NAME
Orkambi, a combination of VX-809 (Lumacaftor) and VX-770 (Ivacaftor)
APPROVED FOR 
Cystic fibrosis (CF) in patients older than 12 with two copies of the 
∆F508 CFTR gene
TYPE
Small-molecules
MOLECULAR TARGETS
CFTR, an anion channel in the ATP binding cassette transporter family
CELLULAR TARGETS
Various epithelial tissues in which CFTR regulates chloride, bicarbonate, 
and fluid secretion
EFFECTS ON TARGETS
Lumacaftor corrects mutant CFTR folding, and Ivacaftor potentiates 
CFTR channel activity.  Restored CFTR trafficking and activity counters 
the fluid secretion defects in pancreas, intestine, sweat glands, and lung, 
where it improves airway surface liquid formation and productive mucus 
and microbe clearance.
DEVELOPED BY
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics
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